ArticleCancers2022

Responses to the Tepotinib in Gastric Cancers with MET Amplification or MET Exon 14 Skipping Mutations and High Expression of Both PD-L1 and CD44.

Sung-Hwa Sohn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.